Figure 1.
An effect of NK cell-based autologous immune enhancement therapy (AIET) combined with a mAb drug. Images of a 55-year-old female patient with metastasis of lung, bone, and skin of breast cancer (invasive ductal carcinoma) post operation. After receiving informed consent from the patient, autologous activated NK cells (2 x 109 cells/injection) were transfused into the patients at 2-week intervals. After failing of most of chemotherapy including trastuzumab, a synergistic effect of NK cell-based AIET, chemotherapy (trastuzumab, taxane, capecitabine) and hyperthermia led to treatment response [5].